RxSight, Inc.
- Open
- 7.07
- Day high
- 7.36
- Day low
- 7.00
- Prev close
- 7.05
- Volume
- 1.3M
- Mkt cap
- $305M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.2
- P/S
- 2.4
- Yield
- —
- Per share
- —
RxSight, Inc. (RXST) is a Healthcare company listed on NASDAQ. The stock is down 19% over the past year. Drillr has 1 published research article covering RXST.
RxSight, Inc. (RXST) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RXST earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 7, 2026 | $-0.33 | $-0.29 | +12.0% | $34M | +3.7% |
| May 6, 2026 | $-0.30 | $-0.38 | -27.1% | $31M | +3.8% |
| Feb 25, 2026 | $-0.23 | $-0.22 | +3.4% | $33M | +0.0% |
| Nov 5, 2025 | $-0.19 | $-0.04 | +78.9% | $30M | -6.9% |
| Aug 7, 2025 | $-0.10 | $-0.08 | +20.0% | $34M | +30.6% |
| May 7, 2025 | $-0.04 | $-0.03 | +25.0% | $38M | -0.0% |
| Nov 7, 2024 | $-0.25 | $-0.16 | +36.0% | $45M | +12.5% |
| Feb 28, 2024 | $-0.36 | $-0.26 | +27.8% | $29M | +4.2% |
| Nov 9, 2023 | $-0.42 | $-0.35 | +16.7% | $31M | +19.0% |
| Mar 6, 2023 | $-0.72 | $-0.56 | +22.2% | $16M | -1.2% |
| May 5, 2022 | $-0.56 | $-0.54 | +3.6% | $9M | +22.2% |
| Mar 8, 2022 | $-0.58 | $-0.47 | +19.0% | $8M | +10.3% |
RXST insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 24, 2026 | Mottiwala Azizdirector, officer: President and CEO | Grant | 2,312,138 | — |
| Jul 24, 2026 | Mottiwala Azizdirector, officer: President and CEO | Grant | 571,286 | $5.19 |
| Jun 18, 2026 | PALMISANO ROBERT Jdirector | Grant | 37,037 | — |
| Jun 18, 2026 | Andrews Juliedirector | Grant | 37,037 | — |
| Jun 18, 2026 | Warner Robert Keithdirector | Grant | 37,037 | — |
| Jun 18, 2026 | Tammenoms Bakker Julietdirector | Grant | 37,037 | — |
| Jun 18, 2026 | COHEN RAYMOND Wdirector | Grant | 30,864 | — |
| Jun 18, 2026 | Corley Jesse Andersondirector | Grant | 37,037 | — |
| Jun 18, 2026 | LINK WILLIAM J PHDdirector | Grant | 37,037 | — |
| Jun 18, 2026 | Fountain Tamaradirector | Grant | 37,037 | — |
| Jun 18, 2026 | Maniar Shwetadirector | Grant | 37,037 | — |
| Apr 20, 2026 | Goldshleger Ilyaofficer: Chief Operating Officer | Option | 12,489 | $4.13 |
| Mar 3, 2026 | Goldshleger Ilyaofficer: Chief Operating Officer | Grant | 32,218 | — |
| Mar 3, 2026 | Wilterding Markofficer: Chief Financial Officer | Option | 20,441 | — |
| Mar 3, 2026 | Gaines Scottofficer: Chief Customer Officer | Grant | 32,218 | — |
Source: RXST SEC Form 4 filings, latest Jul 24, 2026. For informational purposes only — not investment advice.
See the full RXST insider & 13F page →RxSight, Inc. company profile
Overview
RxSight, Inc. (NASDAQ:RXST) is a medical technology company founded in 1997 and headquartered in Aliso Viejo, California. Originally incorporated as Calhoun Vision, Inc., the company changed its name to RxSight in February 2017 and went public in July 2021. RxSight has developed and commercialized the world's first and only adjustable intraocular lens technology for cataract surgery, allowing surgeons to customize patients' vision after the initial surgical procedure. The company primarily serves the United States market with plans for international expansion into Europe and Asia.
Business
RxSight operates in the premium intraocular lens (IOL) segment of the cataract surgery market, which is part of the broader ophthalmology medical device industry. Cataracts are a common age-related condition where the natural lens of the eye becomes cloudy, requiring surgical replacement with an artificial lens called an intraocular lens. The company's core innovation is the RxSight System, which consists of two main components that work together to provide adjustable vision correction: 1. Light Adjustable Lens (LAL) - This is a special intraocular lens made from a proprietary photosensitive silicone material that can be modified after implantation. The LAL comes in two variants: the standard LAL and LAL+, which provides enhanced near vision capabilities. These lenses can be adjusted to correct vision problems like nearsightedness, farsightedness, and astigmatism after the eye has healed from surgery. 2. Light Delivery Device (LDD) - This is an office-based UV light treatment device that delivers precisely programmed patterns of light to modify the LAL lens. The treatment is non-invasive and typically takes just a few minutes per eye. The traditional cataract surgery process involves selecting a lens power before surgery based on pre-operative measurements, but healing and other factors can affect the final visual outcome. RxSight's technology allows surgeons to fine-tune the lens power after surgery when the eye has stabilized, potentially achieving better visual outcomes than conventional IOLs. RxSight generates revenue from two primary sources: LAL sales account for approximately 71% of total revenue, while LDD equipment sales contribute about 29% of revenue. The company has built an installed base of 971 LDD units as of Q4 2024, with strong growth in LAL utilization averaging around 30 lenses per device per month.
Competitive moat
RxSight possesses a strong technological moat based on its proprietary and patented light-adjustable lens technology. The company holds the only FDA-approved adjustable intraocular lens system, creating a significant competitive advantage in the premium cataract surgery market. This technology barrier is substantial because developing competing adjustable lens technology would require years of research, clinical trials, and regulatory approval processes. The company's moat is further strengthened by its growing installed base of LDD devices, which creates switching costs for ophthalmology practices that have invested in the equipment and trained their staff on the technology. The clinical outcomes data showing superior visual results compared to traditional premium IOLs also provides a defensive advantage, as it becomes increasingly difficult for competitors to match these proven results. However, the moat faces potential challenges from several directions. Large ophthalmology companies like Alcon, Johnson & Johnson Vision, and Bausch + Lomb have significant resources to develop competing technologies or potentially acquire RxSight. The premium IOL market also faces competition from alternative vision correction procedures like LASIK or newer surgical techniques. Additionally, if manufacturing costs for traditional premium IOLs decrease significantly, the cost-benefit analysis for RxSight's more expensive technology could become less favorable. The strength of RxSight's moat ultimately depends on maintaining its technological leadership, continuing to demonstrate superior clinical outcomes, and successfully scaling its market penetration before competitors can develop viable alternatives. The company's early-mover advantage and patent protection provide meaningful protection, but sustained investment in R&D will be crucial to maintaining this competitive position long-term.
Risks & safety
RxSight demonstrates a moderate margin of safety with strong balance sheet fundamentals but ongoing profitability challenges. • Liquidity and Solvency: The company maintains a strong current ratio of 12.7x with $28 million in cash and short-term investments. Total debt is minimal at just 4.3% of equity, providing substantial financial flexibility. • Cash Flow Dynamics: Free cash flow remains negative at -$9.4 million in Q1 2025, though this represents improvement from historical burn rates. Operating cash flow of -$8.8 million indicates the company is still investing heavily in growth. • Valuation Metrics: Trading at 3.7x book value with negative EBITDA makes traditional valuation challenging. The Graham net-net ratio of 5.7 suggests the stock trades well above liquidation value. • Growth vs. Profitability Trade-off: Revenue growth of 28% year-over-year demonstrates strong market traction, but the company continues to prioritize market share expansion over near-term profitability. • Market Position Risk: As the sole provider of adjustable IOL technology, the company faces concentration risk if competitive alternatives emerge or if market adoption slows.
Recent development
Over the past few years, RxSight has executed several key strategic initiatives to strengthen its market position and expand its addressable market. The company has significantly enhanced its product portfolio with the introduction of LAL+, which provides improved near vision capabilities and extended depth of focus. This advancement addresses a broader range of patient vision needs and has shown strong clinical results with over 90% of patients achieving both excellent distance and near vision. The company has also expanded the technical capabilities of its platform through FDA approvals for extended diopter ranges and new LDD functionality that allows customization of lens asphericity. These enhancements broaden the range of patients who can benefit from the technology, particularly those with high myopia or specific optical requirements. From a market expansion perspective, RxSight has been systematically building its commercial infrastructure, growing its sales force and expanding its clinical education programs. The company has increased its focus on engaging optometrists as key referral sources and patient counselors, recognizing their expertise in vision correction. Additionally, RxSight has been preparing for international expansion by pursuing regulatory approvals in Europe and Asia, though meaningful international revenue is not expected until 2026. The company has also refined its go-to-market strategy by developing centralized light treatment options to support new customer business models and has leveraged its extensive clinical data to demonstrate the value proposition of adjustable lenses over traditional premium IOLs. These strategic moves position RxSight to capture a larger share of the growing premium IOL market while maintaining its technological leadership.
RXST company profile · for informational purposes only — not investment advice.
Track RXST with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free